Astrotech (NASDAQ: ASTC) subsidiary 1st Detect, in collaboration with The University of Texas Health Science Center, now called UT Health San Antonio, announced positive preliminary results in pre-clinical trials for the BreathDetect 1000 – a rapid bedside breathalyzer for detecting bacterial infections in the respiratory tract, such as hospital-acquired pneumonia (HAP).
Astrotech Corporation’s (NASDAQ: ASTC) board of directors and management announce that they have engaged Chardan to advise on strategic alternatives involving Astrotech subsidiary 1ST Detect Corporation, a manufacturer of advanced mass spectrometry technology used to detect and analyze trace levels of explosives, chemical warfare agents (CWAs), and volatile organic compounds (VOCs).
1ST Detect Corporation, a subsidiary of Astrotech Corporation (NASDAQ: ASTC), announced the United States Patent and Trademark Office (USPTO) issued a key patent for increasing the performance of the company’s unique ion trap mass spectrometer used for chemical analysis and detection. 1ST Detect’s total patent count is now 17 U.S. and 6 international issued, and 7 U.S. and 10 international pending.
Astrotech Corporation (NASDAQ: ASTC) subsidiary 1ST Detect Corporation and strategic partner Battelle Memorial Institute completed the Brassboard Phase and were awarded the Final Prototype Phase of the US military’s Next Generation Chemical Detector (NGCD) Multi-Sample Identifier (MSI) Technology Maturation and Risk Reduction Program.
1ST Detect Corporation was awarded three patents by the United States Patent Office (USPTO) enabling the field use of ion trap chemical analyzers in harsh and demanding environments.